Brigatinib versus crizotinib in patients with ALK...

Lung Cancer 2020 / 01 Vol. 139

Brigatinib versus crizotinib in patients with ALK inhibitor–naive advanced ALK+ NSCLC: results from the phase 3 ALTA-1L trial

Califano, R., Camidge, D., Kim, H.-R., Ahn, M.-J., Yang, J., Han, J.-Y., Hochmair, M., Lee, K.H., Delmonte, A., Campelo, M.R. Garcia, Kim, D.-W., Griesinger, F., Felip, E., Spira, A., Gettinger, S., T
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
139
Journal:
Lung Cancer
DOI:
10.1016/S0169-5002(20)30164-1
Date:
January, 2020
File:
PDF, 56 KB
2020
Conversion to is in progress
Conversion to is failed